ITS BIO

AffinityImmuno Products

ELISA kits, research antibodies, biosimilars and isotype controls from AffinityImmuno.

EL-1611-152

EL-1611-152 image 1

AffinityImmuno · ELISA Kit

Omalizumab (Xolair®) Pharmacokinetic ELISA

Cat.No

EL-1611-152

1X96 wells

Reactivity
Human, mouse, rat
Detection range
50ng/ml - 1.56ng/ml
Sample type
Serum Plasma
Assay time
2.5 hours
Antigen
Omalizumab (Xolair)
Detection minimum
1.5ng/ml

Product Overview

The Omalizumab PK ELISA kit is designed to measure Omalizumab in serum or plasma with high specificity and sensitivity through sandwich technique.

INTRODUCTION

The Omalizumab PK ELISA kit is designed to measure Omalizumab in serum or plasma with high specificity and sensitivity. This sandwich ELISA design employs a Omalizumab specific monoclonal antibody for capture and a specific monoclonal antibody for detection.

PRINCIPLE OF THE ASSAY

This assay employs the sandwich enzyme immunoassay technique. Anti- Omalizumab is coated onto a 96 well microplate. Calibrator and test samples are pipetted into the appropriate wells. Omalizumab present in biological matrices is bound by the immobilized anti- Omalizumab antibody. After washing away any unbound substances, enzyme linked anti- Omalizumab antibody is added to the wells. This antibody is developed and purified specifically against Xolair® (domain residing in Fc portion of the Xolair® molecule). The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Omalizumab present in test samples. The color development is stopped and the intensity of the color is measured

Target background

Omalizumab (Xolair®) is a recombinant DNA-derived humanized IgG1κ monoclonal antibody that binds human immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma and Chronic Idiopathic Urticaria (CIU). Omalizumab inhibits the binding of IgE to IgE receptor (FcεRI) on the surface of mast cells and basophils thereby limiting the release of mediators of the allergic response from the FcεRI bearing cells.

Need assistance?
Contact our experts for support and fast quotations.
(주)이츠바이오
07532 서울특별시 강서구 양천로 551-17 한화비즈메트로 1차 812호
T : 02-3462-8658  F : 02-3462-8659
E-mail : info@itsbio.co.kr
ITSBio, Inc.
812, Hanwha Bizmetro A-dong, 551-17 YangcheonRo, Gangseo-Gu, Seoul, 07532, Korea, Republic of
T : +82-2-3462-8658  F : +82-2-3462-8659
E-mail : info@itsbio.co.kr
Privacy Policy|Terms|© 2026 ITS BIO. All rights reserved.
Online Message
Send to info@itsbio.co.kr